Sign in to fuzzto save your conversations, follow your research and come back anytime.
Torrent Pharmaceuticals
SectorHealthcare
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
In the news
Torrent Pharma's ED Amal Kelshikar Resigns Effective Oct 16
5 Stocks Show 34% Upside Potential with Consistent Score Improvement
Torrent Pharma raises investment to ₹11.88 cr for 26% stake
Torrent Pharma shares rise 2.02% to ₹4,999 on strong Q1 performance
Morgan Stanley upgrades Torrent Pharma, downgrades Mankind
Torrent Pharma gets Neutral rating, target Rs 4730: Motilal Oswal
Torrent, Mankind Pharma Report Strong Q1 Growth on Domestic Demand
Torrent Pharma shares rise 2.18% on strong Q4 results
Torrent Pharmaceuticals shares fall 2.91% despite strong growth
Torrent Pharma, RBL Bank Face MSCI Index Changes on July 16
India's Fat-Loss Drug Market Cooling as Generics Disrupt Premium Imports
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices
Torrent Pharmaceuticals drops 5th straight session, down 0.36%
Prabhudas Lilladher maintains Rs 5000 target for Torrent Pharma
Torrent Pharma surges 3.06% for third straight session
Pharma stocks surge 9% in 2026 with brokerage upside targets
Torrent Pharma hits 52-week high on Q4 results, brokerages see upside
Torrent Pharma Q4 Results Beat Estimates; Nirmal Bang Maintains Hold
Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results
Torrent Pharma Q4 profit drops 22% to ₹389 cr on JB Pharma costs
The Quarter story
The two most recent quarterly results, compared side-by-side.
Torrent Pharma shows steady revenue growth and expanding margins, driven by strong India performance and a healthy international pipeline.
Consolidated revenue grows from ₹3,178 Cr in Q1 FY26 to ₹4,921 Cr in Q1 FY27 — strong volume recovery drives top-line expansion
Brazil revenue falls from ₹907 Cr in Q3 FY26 to ₹455 Cr in Q4 FY26 — post-peak normalization reduces short-term gains
India revenue rises from ₹1,811 Cr in Q1 FY26 to ₹2,890 Cr in Q1 FY27 — steady domestic demand supports consistent growth
US revenue drops from ₹967 Cr in Q3 FY26 to ₹396 Cr in Q4 FY26 — seasonal demand normalization impacts quarterly output
Germany revenue surges from ₹308 Cr in Q1 FY26 to ₹916 Cr in Q3 FY26 — successful market penetration boosts European sales
Others revenue declines from ₹1,563 Cr in Q3 FY26 to ₹112 Cr in Q4 FY26 — volatile non-core streams require closer monitoring
Company insights, generated from the most recent coverage.
Q1 FY27 net profit grew only 3% YoY despite 55% revenue growth, causing net margin to compress from 17.45% to 11.53%.
Germany revenues down 9% in constant currency due to third-party supply disruption and lower tender offtake.
Trading at 87x PE and 9.6x PB, the stock is highly sensitive to earnings disappointments given its rich valuation.